An Encouraging Turn in the Study - Report on Cara Therapeutics Inc.

Jul 31, 2015, 09:20 ET from www.aciassociation.com

NEW YORK, July 31, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ: CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=CARA

Highlights from our CARA Report include:

  • Cara Therapeutics announces statistically significant results - On July 23, 2015, Cara Therapeutics, Inc. announced that the topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP) were statistically significant.
  • The Phase 2 Trial - The Phase 2 Trial conducted by the Company was a double-blind, randomized, placebo-controlled trial devised to evaluate the efficacy of I.V. CR845 compared to placebo in reducing the intensity of itch in dialysis patients over a two-week dosing period. For the trial, Cara Therapeutics enrolled 65 dialysis patients at multiple sites in the United States. According to the Company, the primary endpoint of the Phase 2 trial was the change from baseline of the average worst itching during the second week of treatment, as was recorded on a visual analog scale (VAS).
  • Management Views - Derek Chalmers, Ph.D., D.Sc., the CEO and President of Cara Therapeutics said that the results demonstrated the potential of Cara's lead candidate CR845 to address an additional indication of significant unmet need beyond its lead I.V. CR845 program in acute pain. Joseph Stauffer, D.O., M.B.A., the Chief Medical Officer of the Company said that the management was excited by the topline results in uremic pruritus, as they show that I.V. CR845 holds significant clinical potential in what seems as an indication of significant unmet need for dialysis patients. Dr. James Tumlin, Professor, Department of Medicine, University of Tennessee and a Principal Investigator on the trial said that with no approved therapy and the limited efficacy of current options, CR845 provides an opportunity to relieve the pain and discomfort of this persistent clinical problem among ESRD patients.

To find out how this influences our rating on Cara Therapeutics, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=CARA

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com